Veracyte (VCYT) Accumulated Expenses (2012 - 2026)

Veracyte has disclosed Accumulated Expenses across 15 years of filings, most recently posting $47.7 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 9.08% year-over-year to $47.7 million; the TTM figure through Jun 2026 stood at $47.7 million (up 9.08% YoY), while the FY2025 annual figure was $48.8 million, up 11.35% from the prior year.
• Accumulated Expenses came in at $47.7 million for Q2 2026 at Veracyte, up from $43.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $48.8 million in Q4 2025 to a low of $30.3 million in Q1 2024.
• Average Accumulated Expenses over 5 years is $39.4 million, with a median of $38.5 million recorded in 2022.
• Year-over-year, Accumulated Expenses surged 137.13% in 2022 and declined 20.5% in 2023.
• Over 5 years, Accumulated Expenses stood at $37.8 million in 2022, then rose by 1.73% to $38.4 million in 2023, then grew by 14.05% to $43.8 million in 2024, then grew by 11.35% to $48.8 million in 2025, then decreased by 2.3% to $47.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $47.7 million in Q2 2026, $43.1 million in Q1 2026, and $48.8 million in Q4 2025.